Korean J Med.  2013 Nov;85(5):495-502.

Effects of Angiotensin-Converting Enzyme Polymorphism on Soluble Receptor for Advanced Glycation End-Products in Maintenance Hemodialysis Patients

• Lee KW
• Cha JM
• Lee YM
• Park SD
• Song JH
• Ahn SH

Abstract

BACKGROUND/AIMS
Advanced glycation end-products (AGEs) exert various toxic effects through the receptor for AGEs (RAGE). Soluble RAGE (sRAGE) is a naturally occurring inhibitor of AGE-RAGE. Recent studies have suggested that inhibition of angiotensin-converting enzyme (ACE) reduces the accumulation of AGEs in diabetes partly by increasing the production and secretion of sRAGE into the plasma. This report describes the relationship between sRAGE and ACE polymorphism in maintenance hemodialysis patients.
METHODS
The levels of sRAGE and advanced oxidation protein products (AOPPs) were assessed by enzyme-linked immunosorbent assay (ELISA), and ACE polymorphism was detected by PCR amplification.
RESULTS
The distributions of ACE genotypes in 105 hemodialysis patients were as follows: II, 56 (35.9%); ID, 29 (18.6%); and DD, 20 (12.8%). According to the ACE genotypes, the study group consisted of II (n = 56) and ID + DD group (n = 49). sRAGE was correlated with age (r = -0.24; p = 0.013). There were significant differences in sRAGE, AOPP, age, duration of dialysis, C-reactive protein, or 24-h urine volume between two genotype groups. There were no significant differences in sRAGE levels, even though the effect of age was treated as a covariate.
CONCLUSIONS
Our findings suggested that sRAGE may be affected only by age, and not by ACE polymorphism in maintenance hemodialysis patients.

Keyword

Advanced glycation end-products; Angiotensin-converting enzyme; Polymorphism; sRAGE protein

MeSH Terms

Advanced Oxidation Protein Products
C-Reactive Protein
Dialysis
Enzyme-Linked Immunosorbent Assay
Genotype
Humans
Plasma
Polymerase Chain Reaction
Rage
Renal Dialysis*
Urine
Advanced Oxidation Protein Products
C-Reactive Protein